Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis
@article{AhlstrmEmanuelsson2004TopicalTW, title={Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis}, author={Cecilia Ahlstr{\"o}m-Emanuelsson and M. Andersson and Carl Persson and Camilla Schrewelius and Lennart Greiff}, journal={Clinical \& Experimental Allergy}, year={2004}, volume={34} }
Background Rofleponide palmitate is an esterified glucocorticosteroid pro‐drug with a promising pre‐clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide.
21 Citations
Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis.
- Medicine, BiologyRespiratory medicine
- 2007
Investigational drugs for the treatment of allergic rhinitis
- MedicineExpert opinion on investigational drugs
- 2014
It is the opinion that despite developments in new therapies, a multidrug approach is vital for successful treatment of allergic rhinitis and immunotherapy in the form of sublingual immunotherapy is a promising additional therapeutic approach that will potentially make immunotherapy available to a wider selection of eligible patients.
Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- 2007
New Therapies for Allergic Rhinitis
- MedicineCurrent Allergy and Asthma Reports
- 2014
The aim of this review is to provide an update on allergic rhinitis treatment, paying particular attention to clinical trials published within the past 20 months that assessed the efficacy and safety of new formulations of available drugs or new molecules.
Emerging drugs for perennial allergic rhinitis
- Medicine, BiologyExpert opinion on emerging drugs
- 2012
In the last years there have been very few innovative approaches to optimize the management of AR, and some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development.
Investigational drugs for allergic rhinitis
- Medicine, BiologyExpert opinion on investigational drugs
- 2010
Attempts are currently made to improve the existing molecules and to develop new drugs, in order to achieve greater clinical efficacy with a better tolerability of allergic rhinitis.
Novel, Alternative, and Controversial Therapies of Rhinitis.
- MedicineImmunology and allergy clinics of North America
- 2016
Does Lipophilicity Per Se Induce Adjuvant Effects? Methyl Palmitate as Model Substance Does Not Affect Ovalbumin Sensitization
- BiologyJournal of toxicology and environmental health. Part A
- 2007
Results showed that effects of adjuvants not are necessarily due to their lipophilicity; that is, additional structural properties are required.
Allergic rhinitis: current options and future perspectives
- MedicineCurrent opinion in allergy and clinical immunology
- 2014
Available and new drugs under investigation seem able to control rhinitis symptoms without a significant patient's burden, and the challenge for the next years will be to improve treatment adherence rather than to introduce new drugs.
Emerging drugs for the treatment of perennial allergic rhinitis
- MedicineExpert opinion on emerging drugs
- 2016
The ultimate research goal is beyond symptomatic treatment, and is mainly directed at modifying the immune response to allergens and prevent the progression of allergic rhinitis towards asthma.
References
SHOWING 1-10 OF 14 REFERENCES
Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment
- MedicineClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
- 2001
The occurrence of eotaxin in nasal mucosal surface liquids in patients with seasonal allergic rhinitis without allergen exposure and during repeat allergenic challenge with and without topical glucocorticosteroid treatment is examined.
Glucocorticosteroids and rhinitis
- MedicineAllergy
- 1993
This paper reviews the literature, and presents 20 years' clinical experience of topical GCS treatment for rhinitis, and describes the pathophysiology of the disease and the putative modes of action of GCSs in the nose.
Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis.
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- 1998
Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model.
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- 2000
Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- 1997
Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid.
- MedicineAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- 2002
A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with Seasonal Allergic Rhinitis
- MedicineAmerican journal of rhinology
- 1997
Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/ day fluticasone propionate.
A comparison of the efficacy and safety of inhaled corticosteroids in asthma
- MedicineAllergy
- 1997
The high safety margin of inhaled therapy with GCSs has encouraged an increasingly widespread use of these compounds in patients with moderate to severe asthma over the past 20 years, and especially where high firstpass metabolism to inactive compounds in the liver has been demonstrated.
Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways.
- Biology, MedicineAmerican journal of respiratory and critical care medicine
- 1999
The nature and extent of the ECL and its product indicate that allergen-induced cytolysis is a primary and major mechanism for the release of eosinophil proteins in human allergic airway inflammation in vivo.